Written by Julia Rostova
High Tide’s fiscal third-quarter report gives investors an unusually complete picture of a cannabis retailer moving toward stronger operating leverage. For the three months ended July 31, 2026, the company reported record revenue of C$198.8 million, up 33% year over year and 11% sequentially. Gross profit reached C$52.7 million, adjusted EBITDA reached C$16.2 million, and net income was C$12.7 million. The company’s September 14 release also reported C$7.0 million of free cash flow. The results are materially better than a simple revenue-growth story: operating income increased 133% year over year to C$8.7 million, while adjusted EBITDA grew 53%. That combination merits attention, but it does not remove the execution and regulatory risks that make a full buy call premature.
Revenue quality is central to the thesis. Canna Cabana, High Tide’s Canadian retail business, operated 232 locations at the reporting date and held 14% market share in the provinces where it operates excluding British Columbia. Same-store sales for the overall quarter were consistent with the prior year, although management reported positive comparative growth in June and July. The distinction matters. A flat quarterly same-store-sales result means new stores and adjacent businesses still carried much of the reported top-line growth. Positive recent months may indicate momentum, but they are not yet a substitute for a sustained, reported comparable-sales improvement across a full fiscal period.
The margin data are more encouraging. Gross margin held at 27%, while adjusted EBITDA margin increased to 8.2%, the highest level in 12 quarters according to the company. General and administrative expense was 3.9% of revenue, compared with 4.4% a year earlier, and salaries, wages and benefits were 11.4% of revenue versus 12.2%. These ratios suggest that the company is gaining scale rather than simply buying growth. Adjusted EBITDA is a non-IFRS measure defined and reconciled by High Tide; it is useful for assessing operating performance but excludes items that still affect shareholder returns. Investors should read it alongside GAAP-equivalent net income, cash flow, debt terms and dilution.
Free cash flow is the most important corroborating signal. High Tide reported C$11.9 million of operating cash flow before changes in non-cash working capital and C$7.0 million of free cash flow. This is significant because a large retail footprint can consume cash through new leases, build-outs, inventory and integration activity even when accounting earnings improve. Cash and cash equivalents, including restricted cash, were C$47.1 million at July 31. Subsequently, the company closed C$40 million of senior secured credit facilities with Bank of Montreal. The facility can provide flexibility, but debt availability is not the same as balance-sheet de-risking; borrowing costs, covenants and the pace of store expansion remain material considerations.
Germany is the second engine investors should track. Remexian, High Tide’s medical-cannabis distribution business, delivered 10.2 tonnes in the fiscal third quarter, up 62% year over year and 35% sequentially. The unit generated C$38.2 million of revenue and a 26% gross margin. A distribution model can diversify High Tide beyond Canadian retail, yet it adds exposure to import rules, medical-market competition, supplier relationships and changing European regulation. The company’s assertion that Remexian’s market share rose to 10.5% is useful directional evidence, but it should be tested in future filings against segment profitability and working-capital requirements, not just shipment volume.
HITI closed at $2.54 on the Nasdaq on September 15 in the dated market snapshot. The $2.70 target is a transparent technical-reference level based on the observed September 14 five-day high, implying 6.29% appreciation. It is not an intrinsic-value estimate, discounted-cash-flow output, management forecast or sell-side consensus. This deliberately limited target reflects a cross-currency problem: the company reports its operating results in Canadian dollars, while the quoted Nasdaq price is in U.S. dollars, and the release does not provide full-year per-share guidance that would permit a disciplined earnings-multiple target.
The explicit verdict is Hold. High Tide has delivered credible signs of improving scale economics, free-cash-flow generation and German distribution growth. However, the same-store-sales result was flat for the reported quarter, the business remains expansion-intensive, and cannabis regulation can alter market economics quickly. A more constructive verdict would require repeated comparable-sales growth, durable free cash flow after expansion investment, and evidence that the credit facility supports returns rather than masks capital intensity. A weaker result would follow if new locations, working capital or regulatory shifts erode the margin progress now visible in the quarter.
Informational/educational only, not financial advice. Do your own due diligence. Past performance does not equal future results.
